Sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists are now recommended in treating diabetes among individuals with CVD, with strong evidence supporting their effectiveness in reducing major adverse cardiovascular events (MACEs) and improving glycemic control [39]. This evidence concerns the gene SLC5A2 and diabetes mellitus.